These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16900015)

  • 21. Cardiovascular disease prevention tailored for women.
    Engberding N; Wenger NK
    Expert Rev Cardiovasc Ther; 2008 Sep; 6(8):1123-34. PubMed ID: 18793115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost and effectiveness of cardiovascular prevention.
    Boyar A
    Am J Cardiol; 2007 Nov; 100(9):1492-4; author reply 1494-5. PubMed ID: 17950815
    [No Abstract]   [Full Text] [Related]  

  • 23. Bibliography. Current world literature. Prevention.
    Curr Opin Cardiol; 2006 Sep; 21(5):535-54. PubMed ID: 17001789
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevalence and predictors of nonfatal myocardial infarction in Jordan.
    Nsour M; Mahfoud Z; Kanaan MN; Balbeissi A
    East Mediterr Health J; 2008; 14(4):818-30. PubMed ID: 19166165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost of cardiac arrest in the workplace.
    Ambrose R
    Occup Health Saf; 2004 Sep; 73(9):88, 90, 202. PubMed ID: 15497579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group.
    Arnett DK; Baird AE; Barkley RA; Basson CT; Boerwinkle E; Ganesh SK; Herrington DM; Hong Y; Jaquish C; McDermott DA; O'Donnell CJ; ; ;
    Circulation; 2007 Jun; 115(22):2878-901. PubMed ID: 17515457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic syndrome is a predictor for an ECG sign of no-reflow after primary PCI in patients with acute ST-elevation myocardial infarction.
    Tartan Z; Ozer N; Uyarel H; Akgul O; Gul M; Cetin M; Kasikcioglu H; Cam N
    Nutr Metab Cardiovasc Dis; 2008 Jul; 18(6):441-7. PubMed ID: 17981019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [HAART influences the lipids].
    Behrens G
    MMW Fortschr Med; 2009 Apr; 151(18):36-8. PubMed ID: 19769073
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphisms that predict outcome and need for treatment in cardiovascular disease.
    Yende S; Wunderink RG
    Curr Opin Crit Care; 2006 Oct; 12(5):420-5. PubMed ID: 16943719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic syndrome, diabetes and atherosclerosis: influence of gene-environment interaction.
    Andreassi MG
    Mutat Res; 2009 Jul; 667(1-2):35-43. PubMed ID: 19028510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal medical treatment of cardiovascular risk factors: can we prevent the development of heart failure?
    Alba AC; Delgado DH
    Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):147-57. PubMed ID: 19210211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal risk factor modification and medical management of the patient with peripheral arterial disease.
    Chi YW; Jaff MR
    Catheter Cardiovasc Interv; 2008 Mar; 71(4):475-89. PubMed ID: 18307227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The protective effect of risk factors against stroke severity.
    Steiner I; Gotkine M; Wirguin I
    J Neurol Sci; 2008 Apr; 267(1-2):187-8. PubMed ID: 18068188
    [No Abstract]   [Full Text] [Related]  

  • 36. Intracardiac lipid accumulation, lipoatrophy of muscle cells and expansion of myocardial infarction in type 2 diabetic patients.
    Borisov AB; Ushakov AV; Zagorulko AK; Novikov NY; Selivanova KF; Edwards CA; Russell MW
    Micron; 2008 Oct; 39(7):944-51. PubMed ID: 18093836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research.
    Kavey RE; Allada V; Daniels SR; Hayman LL; McCrindle BW; Newburger JW; Parekh RS; Steinberger J; ; ; ; ; ; ; ; ;
    J Cardiovasc Nurs; 2007; 22(3):218-53. PubMed ID: 17545824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myocardial infarction: an important factor for surgical decision making?
    Osswald BR; Tochtermann U; Keller S; Badowski-Zyla D; Gegouskov V; Thomas G; Jakob HG; Hagl S
    Thorac Cardiovasc Surg; 2009 Apr; 57(3):130-4. PubMed ID: 19330748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of metabolic syndrome on future cardiovascular events in patients with first acute myocardial infarction.
    Selcuk H; Temizhan A; Selcuk MT; Sen T; Maden O; Tekeli S; Sasmaz A
    Coron Artery Dis; 2009 Sep; 20(6):370-5. PubMed ID: 19609207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention and rehabilitation as a means of cost containment: the example of myocardial infarction.
    Luginbuhl WH; Forsyth BR; Hirsch GB; Goodman MR
    J Public Health Policy; 1981 Jun; 2(2):103-15. PubMed ID: 6788801
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.